Scripta Therapeutics

Based in the UK, Scripta Therapeutics specializes in innovative drug discovery solutions, employing advanced techniques to address neurodegenerative disorders such as Alzheimer’s and Parkinson’s through transcription factor modulation. Founded in 2025 in Oxford, UK, Scripta Therapeutics is focused on developing solutions for neurodegenerative diseases. The company raised EUR 10. 3 million in Seed funding on November 13, 2025, with investors including AlbionVC, Apollo Health Ventures, Oxford Sciences Enterprises, Parkwalk Advisors, and YZR.

This funding will support their ongoing development efforts. Scripta Therapeutics specializes in innovative drug discovery solutions, focusing on the manipulation of transcription factors to address neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and ALS. The company employs advanced AI/ML models to identify and predict molecules and targets that modulate transcription factor activity, enabling the development of therapeutics aimed at halting or even reversing disease progression. Their approach starts with genome-wide mapping of transcription factors that drive disease, followed by validation of therapeutic candidates in pre-mapped, patient-derived models.

Scripta's services cater primarily to pharmaceutical and biotechnology companies engaged in drug development, providing transformative insights into disease biology relevant to key global markets, including North America and Europe. Scripta Therapeutics has recently secured EUR 10. 3 million in Seed funding to further its mission of developing disease-modifying therapeutics. Revenue is generated primarily through partnerships and collaborations with pharmaceutical companies seeking innovative approaches to drug discovery, particularly those that involve transcription factor modulation.

Transactions typically involve collaborative agreements where Scripta provides its proprietary insights and predictive models in exchange for funding and potential revenue-sharing arrangements. The company’s flagship offerings include its transcription-factor-centered drug discovery services, which are integral to the therapeutic development process for its partners. Specific pricing structures for these services are established during negotiations with clients, reflecting the customized nature of the solutions provided. With the recent EUR 10.

3 million in Seed funding co-led by Oxford Sciences Enterprises and Apollo Health Ventures, Scripta Therapeutics plans to advance preclinical studies and support the development of therapies targeting transcription factors in neurodegenerative diseases. The company intends to expand its reach into additional markets in North America and Europe by 2026, with a focus on releasing new therapeutic products that leverage their proprietary insights and AI-driven models.